| EMA number | EMEA/H/C/004413 |
| ATC code | L03AA13 |
| Authorisation | 21 September 2018 |
| Withdrawn | 4 February 2021 |
| Revision | 3 |
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
NYVEPRIA — HOSPIRA INC, approved 2026-05-21 (BLA761111).
79,576 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.